Evidence map›Paper›PMID 36389291›Full record

ArticleJournal of thoracic disease2022

The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer.

Camille V Edwards, Ayesha R Sheikh, Michael J Dennis, Andrew Hunter, Zoe P Mackay, Evan C Catudal, Rawad Elias, Howard J Cabral, Shayna R Sarosiek, Umit Tapan

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Camille V EdwardsSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Ayesha R SheikhSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Michael J DennisSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Andrew HunterSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Zoe P MackayBoston University School of Medicine, Boston, MA, USA.
Evan C CatudalBoston University School of Medicine, Boston, MA, USA.
Rawad EliasSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Howard J CabralBoston University School of Medicine, Boston, MA, USA.
Shayna R SarosiekSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Umit TapanSection of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.
Boston Medical Center · USDana-Farber Cancer Institute · USHartford Hospital · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Clinical Addiction Research and Education ProgramR25DA013582 · NIDA · BOSTON MEDICAL CENTER · PI JEFFREY H. SAMET, Alexander Yale Walley · 2001 to 2026
$8.9M
NCATS NIH HHS UL1 TR001430NIDA NIH HHS R25 DA013582
6 · The paper itself

Abstract

Background: Mortality from non-small cell lung cancer (NSCLC) has improved with screening and novel treatments. The substance use epidemic has threatened health outcomes in a variety of diseases, but little is known about how it is associated with NSCLC outcomes. Methods: We performed a retrospective cohort study of 211 patients with NSCLC treated at a safety-net hospital. Sociodemographic data and clinical outcomes were extracted via review of electronic medical records. Patients were stratified based on substance use status. Comparative and multivariable analyses were performed to evaluate baseline characteristics and lung cancer outcomes including survival. Results: Among 193 patients (91.5%) with information available on substance use, 24.9% reported substance use; specifically, alcohol, marijuana, and illicit substances. Patients with substance use were more likely to have increased health care utilization and poor social determinants of health, including safe housing, stable employment, and social support. There were no significant differences in treatment adherence. Only 6.3% of patients with substance use did not receive guideline concordant care (GCC) compared to 24.8% of patients without substance use; due to poor performance status, increased comorbidities, or loss to follow up. On univariable analysis, patients with substance use experienced inferior median overall survival (OS) if they had metastatic disease (0.40 Conclusions: Substance use is associated with poor social determinants of health and increased health care utilization. On multivariable analysis, substance use was not independently associated with OS once guideline-concordant care was used. Future studies should focus on improving our understanding of these associations, delineating potential mechanisms, and developing evidence-based strategies to reduce health care utilization and overcome challenges related to poor social determinants of health.

Indexed as

healthcare utilizationnon-small cell lung cancer (NSCLC)outcomesSubstance use

Identifiers

PMID36389291
PMCPMC9641327
OpenAlexW4307809010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.